Article
Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.
Clinical drug investigation - 1 Jul 2017
Puenpatom Amy, Hull Michael, McPheeters Jeffrey, Schwebke Kay
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) is a risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD). Direct-acting antiviral agents (DAAs) have improved HCV management in CKD patients, however real-world clinical practice data are limited. OBJECTIVE: This study examined the prevalence of CKD among HCV patients receiving oral DAAs in a real-world setting. Comorbidities, early discontinuation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.